Jazz Pharmaceuticals Hits High On Gentium Acquisition
Wall Street gave positive reviews to Jazz Pharmaceuticals’ (JAZZ) decision to acquire Italian biotech Gentium (GENT) Friday morning, as both stocks rose on the stock market today. Late Thursday, Jazz said it agreed to buy Gentium for $57 a share, or about $1 billion. The press release highlighted the recent approval of Gentium drug Defitelio (defibrotide) for a rare condition called severe hepatic veno-occlusive disease, which afflicts people